Evenity
News/ News/ Sales and Marketing
Cancer update buoys Amgen despite Q2 sales fall
Phil Taylor
Aimovig, Amgen, Evenity, financial results, Neulasta, Oncology, Repatha
0 Comment
X
Cancer update buoys Amgen despite Q2 sales fall
https://pharmaphorum.com/news/cancer-update-buoys-amgen-despite-q2-sales-fall/
X
CHMP says no to Amgen’s osteoporosis drug Evenity
https://pharmaphorum.com/news/chmp-says-no-to-amgens-osteoporosis-drug-evenity/
X
At long last, Amgen/UCB score FDA okay for Evenity
https://pharmaphorum.com/news/at-long-last-amgen-ucb-score-fda-okay-for-evenity/
News/ News/ Sales and Marketing
Amgen and UCB re-file Evenity for US approval
Piotr Wnuk
Amgen, Evenity, fda, monoclonal antibody, osteoporosis, UCB
0 Comment
X
Amgen and UCB re-file Evenity for US approval
https://pharmaphorum.com/news/amgen-ucb-evenity-fda-filing/